2023-03-19 05:30:00 ET
Over time, Biogen (NASDAQ: BIIB) created a true success story. The biotech company built up an impressive portfolio of multiple sclerosis (MS) drugs and generated billions of dollars in earnings. The share price followed, climbing more than 20,000% from its initial public offering to its peak about eight years ago.
But recent years haven't been as easy. Competition for Biogen's MS blockbuster Tecfidera, and for other key products, entered the market. That's resulted in sales declines -- and questions about where growth will come from down the road.
Now, though, Biogen may have found that new growth source. And a regulatory decision in July may make things official. Should you buy Biogen before the July news? Let's find out.
For further details see:
Should You Buy Biogen Before a Big July Decision?